Full-Time
Strategic Accounts Regional Vice President
RapidAI
201-500 employees
AI-powered medical imaging for stroke care
Compensation Overview
$180k - $200k/yr
United States
Hybrid
East or Midwest USA residency required; travel up to 50% to meet customers.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to RapidAI
See people who can refer or advise you
- Educational Background: A Bachelor’s degree or equivalent related professional experience.
- Core Sales Experience: 10+ years of sales experience in healthcare or medical device sales.
- Management & Account Expertise: 5+ years of sales management experience for global, national, or key strategic account businesses, with a high level of successful experience selling to or working directly in Strategic Accounts.
- Relationship & Influence: Proven executive presence with the ability to build, manage, and maintain complex relationships with senior stakeholders and decision-makers.
- Consultative Strategy: Strong analytical, strategic planning, and execution skills. Consultative selling skills must exhibit a wide range of independent decision-making and control.
- Business & Financial Acumen: High level of financial and business acumen, with the ability to analyze and solve problems of varying degrees of complexity, while driving pricing integrity.
- Market Literacy: Ability to understand and apply market intelligence, healthcare policy, and delivery systems to sales strategy.
- Professionalism & Collaboration: Demonstrated professionalism, dependability, collaboration, and excellent interpersonal and communication skills.
- Software Fluency: Ability to use technology and analysis tools effectively (including Excel, Outlook, and Salesforce).
- Operational Flexibility: Ability to travel up to 50% to meet customers in the field.
- Results-Oriented: A proven track record of meeting or exceeding sales targets.
- Target Areas: Candidates must ideally be located within the East or Midwest areas of the USA.
- Travel: Ability to travel up to 50% to meet customers within your assigned regional field.
- Account Management: Execute existing contracts, own the renewal process, and solidify and expand existing Strategic Account customer relationships.
- Relationship Cultivation: Establish, nurture, and maintain strong, long-lasting relationships with Strategic Account/health system executives, key decision-makers, and influential stakeholders.
- Strategic Planning: Develop and execute strategic sales plans to achieve revenue targets, and pursue identified business prospects by actively participating in the planning and sales process for new opportunities.
- Enterprise Contracts & Negotiations: Lead contract negotiations to ensure favorable terms while maintaining win-win partnerships; when necessary, represent the company with customers, suppliers, government departments, and key contacts to secure the most effective terms for RapidAI.
- Cross-Functional Collaboration: Partner with commercial teams and leadership to drive tactical plans; collaborate with internal departments (product development, sales, marketing, customer support, finance, legal, and compliance) to ensure seamless execution and regulatory adherence.
- Marketing & Training Partnership: Partner with marketing to develop health system engagement tools aimed at driving executive-level exchanges. Partner with sales and training to implement ongoing Strategic Account management training for the commercial sales team.
- Market Intelligence: Stay current with industry trends, healthcare regulations, and competitive landscapes within the healthcare sector to anticipate market shifts, changes in policy, and competitive pressures.
- Data-Driven Performance: Utilize data and analytics to identify opportunities for growth, track and report on sales metrics/KPIs, and adjust strategies as needed.
- Sales Culture: Implement the company's sales process to establish a culture of consultative selling to decision-makers at all levels.
- Team Structure & Support: Operate effectively in an individual contributor capacity, as this position does not have direct reports. Perform any other related activities assigned by the reporting manager.
RapidAI offers an AI-powered medical imaging and workflow platform for vascular and neurovascular care, with a focus on stroke and aneurysm. It analyzes CT and MRI scans to produce imaging data and actionable insights that speed and improve diagnosis and treatment. The platform integrates into hospital workflows to support triage, case management, and treatment planning across 2,000+ hospitals in 50+ countries. Its goal is to improve outcomes in neurovascular emergencies by combining advanced imaging analytics with end-to-end clinical workflows.
Company Size
201-500
Company Stage
Series C
Total Funding
$100.5M
Headquarters
Menlo Park, California
Founded
2012
Get referred to RapidAI
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 2026 St. Luke’s AngioFlow rollout saved at least 35 minutes per case.
- February 2026 ISC brought 28 abstracts, reinforcing clinical validation and sales credibility.
- Saudi HHC and Alaska partnerships expand RapidAI into large, underserved, and distributed systems.
What critics are saying
- Viz.ai and Brainomix keep pressuring RapidAI on workflow and distal-occlusion performance in 2026.
- Hospital implementations stall when PACS, EMR, and operating-room workflows resist integration delays.
- If FDA scrutiny tightens around autonomous imaging claims, RapidAI’s expansion engine slows quickly.
What makes RapidAI unique
- November 2025 FDA clearances made RapidAI the only non-contrast CT intracranial hemorrhage detector.
- RapidAI’s 2026 ISC abstracts show deep clinical AI beyond triage, including tracking and quantification.
- November 2025 Saudi HHC deal embeds RapidAI across 20 health clusters and multiple specialties.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Stock Options
Phone/Internet Stipend
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 2%Rapid AI, a healthcare technology company present in 2,500 hospitals across 100 countries, is leveraging artificial intelligence to transform the $5 trillion US healthcare industry. The company, which emerged from Stanford University 11 years ago, now operates in 75% of comprehensive stroke centres in the US. Dr David Stoffel, Rapid AI's Chief Business Officer and veteran of surgical robotics, believes AI will deliver significant improvements in patient outcomes. Recent advances in deep learning, cloud computing, data analytics and processing speed have created conditions for healthcare breakthroughs. Whilst AI has supported medicine for decades in areas like drug discovery and surgical robotics, the technology must now demonstrate clinical efficacy, satisfy regulators and integrate into existing workflows to gain widespread physician trust and adoption.
Game-Changing stroke care technology. calendar_today May 01, 2026 schedule 3 min. read Left to right, St. Luke's endovascular neurosurgeons Drs. Evan Marlin and Nathan Quig and neurointerventional radiologist Dr. Martin Oselkin, with RapidAI AngioFlow technology displayed on the monitor illustrating real time cerebral blood flow assessment. St. Luke's University Health Network has become the first health care system in Pennsylvania and one of the first nationwide to implement AngioFlow(TM) by RapidAI, a breakthrough perfusion imaging technology. AngioFlow is an advanced brain blood flow imaging tool used for acute stroke evaluation, said Dr. Martin Oselkin, neurointerventional radiologist. Traditionally, patients are sent to a CT scanner for perfusion imaging to help physicians make the decision for thrombectomy (clot removal) or not, but AngioFlow allows St. Luke's to skip the CT scanner and perform the perfusion study right in the operating room. "This results in at least 35 minutes in time saved," Oselkin explained, "which is vital to patient outcomes, as 1 million brain cells die with each minute that passes before a clot is removed." The advancement further strengthens St. Luke's position as the regional leader in advanced stroke diagnosis and treatment - and is a testament to St. Luke's overall excellence. This past fall, the U.S. Department of Health and Human Services ranked St. Luke's #1 - ahead of Houston Methodist and Mayo Clinic, two of the nation's most prestigious institutions - as the nation's top health system for quality, safety, and patient experience. This objective recognition, based on public data reported to the government, reaffirmed St. Luke's preeminent position among the leading health systems in the country. AngioFlow is now available at St. Luke's University Hospital in Bethlehem, a Comprehensive Stroke Center recognized for providing the highest and most advanced level of stroke care and serving as the Network's hub for leading stroke and neurovascular capabilities. For patients, the benefits are significant. Real-time perfusion imaging supports: * Shorter procedure times, which can directly improve outcomes in stroke. * Earlier identification of salvageable brain tissue, increasing the chance of functional recovery. * More precisely tailored interventions, reducing the risk of complications. * Enhanced safety, as clinicians have immediate insight into how treatment is affecting blood flow in real time. At St. Luke's, these advanced stroke and neurovascular interventions are performed by Oselkin and endovascular neurosurgeons Dr. Evan Marlin and Dr. Nathan Quig. Together, they lead the Network's commitment to elevating stroke care across the region through innovation, rapid response and leading-edge technology.
RapidAI presented 28 scientific abstracts at ISC 2026. RapidAI unveiled 28 scientific abstracts at ISC 2026, demonstrating how its FDA-cleared AI solutions enhance stroke detection, aneurysm monitoring, and radiology workflows, leading to improved accuracy and efficiency. Feb. 9, 2026 RapidAI announced details of 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, held February 4-6, at the Ernest N. Morial Convention Center in New Orleans. The abstracts spanned aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization. Findings reflect the impact of deep clinical AI delivered through the Rapid Enterprise platform, designed to scale across radiology and acute workflows. The clinical data demonstrates how RapidAI's clinically validated, FDA-cleared AI solutions can improve diagnostic performance, reduce interpretation time, and deliver measurable efficiency and economic gains for stroke teams and radiology departments. Rapid's Deep Clinical AI, delivers real results by providing not just triage notifications but also visualization, localization, characterization, and tracking changes over time.
RapidAI partners with Saudi Arabia's largest healthcare provider to advance Vision 2030 goals. RapidAI, a pioneer in deep clinical AI and intelligent imaging technology, has formed a strategic partnership with Health Holdings Company (HHC), Saudi Arabia's largest healthcare provider, to deploy advanced artificial intelligence systems across HHC's 20 health clusters nationwide. The collaboration represents a significant international expansion for the San Mateo-based company and directly supports the Health Sector Transformation Program, a key pillar of Saudi Arabia's Vision 2030 initiative aimed at modernizing the Kingdom's healthcare infrastructure. Enterprise-Scale AI deployment across 20 health clusters. According to the company, the partnership establishes RapidAI as HHC's enterprise provider of deep clinical AI, with implementation planned across neurology, cardiology, vascular, oncology, and orthopedic specialties. HHC provides healthcare services to more than 20 million people across Saudi Arabia through its network of hospitals and clinics, making this one of the largest regional deployments of clinical AI technology in the Middle East. The implementation will utilize RapidAI's Enterprise Platform and radiology solutions, integrating into existing clinical, radiology, and IT workflows to support care coordination and collaboration across departments and facilities. Ascend Solutions, a digital healthcare provider in the Saudi market, will provide on-the-ground operational services, including implementation, training, and optimization tailored for HHC's clinical teams and IT infrastructure. "Partnering with RapidAI aligns perfectly with our goal to transform and innovate on how care is delivered across our hospitals, from stroke to cardiac, vascular, and oncology, and to localize these capabilities for the Kingdom's Vision 2030." - Nasser Al Huqbani, CEO of Health Holdings Company "Partnering with RapidAI aligns perfectly with our goal to transform and innovate on how care is delivered across our hospitals, from stroke to cardiac, vascular, and oncology, and to localize these capabilities for the Kingdom's Vision 2030," said Nasser Al Huqbani, CEO of Health Holdings Company. Advancing Saudi Vision 2030 healthcare goals. The partnership directly supports Saudi Arabia's Health Sector Transformation Program, which aims to enhance healthcare quality and accessibility across the Kingdom. The program, established in 2022 under Vision 2030, focuses on transitioning healthcare delivery through digital transformation, value-based care models, and public-private partnerships. Vision 2030 represents Saudi Arabia's strategic framework to diversify its economy and transform public services, with healthcare as a major focus area. The Kingdom's healthcare transformation includes plans to establish health clusters as accountable care organizations, expand digital health capabilities, and attract international partnerships to support infrastructure modernization. According to the Health Sector Transformation Program, Saudi Arabia is working to reduce preventable mortality from non-communicable diseases, increase life expectancy from 75 to 80 years by 2030, and ensure universal health coverage for all citizens and residents. The deployment of advanced clinical AI systems like RapidAI's platform supports these objectives by enhancing diagnostic capabilities and care coordination across the Kingdom's healthcare network. Deep clinical AI for multiple disease states. RapidAI's approach to clinical AI emphasizes solving clinical problems rather than simply detecting conditions. The company's technology goes beyond basic triage alerts to provide what it describes as "deep clinical AI" capabilities, including characterization, quantification, visualization, and longitudinal tracking of clinical conditions. The company reports its solutions are currently deployed in more than 2,500 hospitals across 100 countries, with validation supported by over 700 clinical studies. The multi-specialty deployment approach allows HHC's clinical teams to utilize AI-powered tools across various disease states, potentially improving diagnostic speed and accuracy while supporting more coordinated care delivery across the health cluster network. Strategic implications for Middle East healthcare technology. The RapidAI-HHC partnership signals growing momentum for clinical AI adoption in the Middle East, particularly as Gulf nations invest heavily in healthcare infrastructure and digital transformation. Saudi Arabia's commitment to healthcare modernization, backed by substantial government funding, creates opportunities for international healthcare technology companies to establish regional partnerships. For RapidAI, the partnership provides a substantial foothold in a strategically important market and demonstrates the scalability of its Enterprise Platform across large, distributed healthcare networks. The collaboration also highlights the increasing importance of localization capabilities, with Ascend Solutions providing culturally and linguistically appropriate implementation support for Saudi clinical teams. The partnership structure - combining international technology expertise with local implementation capabilities - may serve as a model for future healthcare AI deployments in the region as other Gulf nations pursue similar digital transformation initiatives. Implementation timeline and regional impact. While specific implementation timelines were not disclosed in the announcement, the partnership positions HHC to accelerate its digital transformation strategy across all 20 health clusters. The scale of the deployment - spanning multiple disease states and clinical specialties across a nationwide network - represents a significant commitment to AI-enabled care delivery. For Saudi patients, the deployment of RapidAI's technology across HHC facilities could mean faster diagnosis and treatment for time-sensitive conditions like stroke and cardiac emergencies, along with improved care coordination as patients move between facilities within the health cluster system. The focus on prevention and early detection aligns with Vision 2030's emphasis on preventive care and reducing the burden of chronic disease. As Saudi Arabia continues its healthcare transformation journey, partnerships like this one between established international technology providers and the Kingdom's largest healthcare institution demonstrate the practical implementation of Vision 2030's ambitious healthcare goals, translating policy objectives into operational reality for millions of patients across the Kingdom. - This original article was created with AI support.
New real-world data presented at this year's European Stroke Organisation Conference (ESOC) suggests that RapidAI's software more accurately identifies medium vessel occlusions (MeVOs) than Viz.ai in stroke patients.